Regeneron Pharmaceuticals Inc. and Sanofi won U.S. Food and Drug Administration approval for their first immuno-oncology drug, a therapy that the companies hope will jump-start their cancer joint venture.
Libtayo, also known as cemiplimab, treats a deadly form of skin cancer.
